Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials (Q24795452)

6 July 2017

1 reference

20 January 2021

1 reference

Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials (English)

1 reference

6 July 2017

prostatic hypertrophy

1 reference

13 November 2019

1 reference

13 November 2019

1 reference

20 January 2021

1 reference

2

R Andrew Moore

1 reference

6 July 2017

Jayne E Edwards

1

1 reference

PubMed ID

12477383

6 July 2017

language of work or name

English

0 references

publication date

12 December 2002

4 references

6 July 2017

2 October 2019

13 November 2019

20 January 2021

4 references

6 July 2017

2 October 2019

13 November 2019

20 January 2021

2

1 reference

6 July 2017

1

0 references

page(s)

14

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2490-2-14

6 July 2017

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1471-2490-2-14

cites work

Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Misleading funnel plot for detection of bias in meta-analysis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

The number needed to treat: a clinically useful measure of treatment effect

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Natural history of benign prostatic hyperplasia

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Medical therapy for benign prostatic hyperplasia: a review of the literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

A systematic review of Cernilton for the treatment of benign prostatic hyperplasia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Sexual dysfunction in the United States: prevalence and predictors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

The importance of quality of primary studies in producing unbiased systematic reviews

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

The effect of finasteride on prostate specific antigen: review of available data

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Natural history of prostatism: risk factors for acute urinary retention

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Scandinavian Clinical Study of Finasteride in the Treatment of Benign Prostatic Hyperplasia

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstructio

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

The value of multiple free-flow studies in men with lower urinary tract symptoms

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

Some patients don't need analgesics after surgery.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=140032

The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years

28 November 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Durability of results obtained with transurethral microwave thermotherapy in the treatment of men with symptomatic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

[Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study]

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Sexual problems: a study of the prevalence and need for health care in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Repeated pressure-flow studies in the evaluation of bladder outlet obstruction due to benign prostatic enlargement. Finasteride Urodynamics Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-2-14

Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12477383

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12477383

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12477383

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2490-2-14

1 reference

PubMed ID

12477383

Dimensions Publication ID

6 July 2017

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1471-2490-2-14

PMCID

140032

1 reference

6 July 2017

1 reference

PubMed ID

12477383